RTSL Stock Overview
Rapid Therapeutic Science Laboratories, Inc.
Rapid Therapeutic Science Laboratories, Inc. Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$2.40|
|52 Week High||US$12.50|
|52 Week Low||US$1.62|
|1 Month Change||13.74%|
|3 Month Change||-40.00%|
|1 Year Change||-70.91%|
|3 Year Change||n/a|
|5 Year Change||-88.56%|
|Change since IPO||-82.55%|
Recent News & Updates
|RTSL||US Medical Equipment||US Market|
Return vs Industry: RTSL underperformed the US Medical Equipment industry which returned -20.3% over the past year.
Return vs Market: RTSL underperformed the US Market which returned -11.7% over the past year.
|RTSL Average Weekly Movement||n/a|
|Medical Equipment Industry Average Movement||9.4%|
|Market Average Movement||7.7%|
|10% most volatile stocks in US Market||16.9%|
|10% least volatile stocks in US Market||3.2%|
Stable Share Price: Insufficient data to determine RTSL's volatility over the past 3 months.
Volatility Over Time: Insufficient data to determine RTSL's volatility change over the past year.
About the Company
Rapid Therapeutic Science Laboratories, Inc. operates as a biotech company. The company engages in the aerosol delivery of non-psychoactive cannabinoids to the blood stream for treatment of chronic pain, post-traumatic stress disorder, insomnia, surgery recovery, and other ailments. It offers pressurized meter dose inhaler, a device that delivers a measured amount of aerosolized inhalant in a mist to the lungs; sublingual oral spray devices; and water-soluble cannabidiol and cannabigerol isolates under the nhaler brand.
Rapid Therapeutic Science Laboratories, Inc. Fundamentals Summary
|RTSL fundamental statistics|
Is RTSL overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|RTSL income statement (TTM)|
|Cost of Revenue||US$200.00|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
|Earnings per share (EPS)||-0.51|
|Net Profit Margin||-732,937.83%|
How did RTSL perform over the long term?See historical performance and comparison